Condition
Rifaximin
Total Trials
5
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
5Total
Early P 1 (1)
P 1 (1)
P 2 (1)
P 3 (1)
P 4 (1)
Trial Status
Not Yet Recruiting3
Unknown2
Clinical Trials (5)
Showing 5 of 5 trials
NCT07522255Phase 3Not Yet Recruiting
Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders
NCT07203846Phase 4Not Yet Recruiting
Modulation of Gut MicroFLORA With Rifaximin to Reduce High Platelet Reactivity in Post-ACS Patients on Ticagrelor
NCT06783153Phase 1Not Yet Recruiting
Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients
NCT05786859Early Phase 1Unknown
The Efficacy and Safety of Rifaximin Treatment
NCT03962283Phase 2Unknown
Rifaximin and Misoprostol Combination Therapy for Healing of Small Bowel Ulcers in Aspirin Users
Showing all 5 trials